<DOC>
	<DOCNO>NCT02071368</DOCNO>
	<brief_summary>The purpose study assess bioequivalence ( similarity drug amount blood among formulation ) fix dose combination ( two component combine one tablet ) canagliflozin metformin extend release ( XR ) tablet ( dose 2 X 150 mg/500mg ) respect individual component canagliflozin ( 1 x 300 mg ) metformin XR tablet ( 2 x 500 mg ) healthy fed participant .</brief_summary>
	<brief_title>A Bioequivalence Study Fixed Dose Combination Tablets Canagliflozin Metformin Extended Release ( XR ) With Respect Individual Components Healthy Fed Participants</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( physicians participant know identity assign treatment ) , single-center , single-dose , 3-treatment , 3-way crossover ( medication provide participant different sequence ) study Fixed Dose Combination ( FDC ) tablets canagliflozin ( CANA ) metformin extend release ( MET XR ) comparison tablet individual component . Two FDC tablet study different formulation MET XR component ( CANA component identical ) . Both FDCs strength : 2 tablet 150mg CANA/500mg MET XR compare equal dos individual drug : canagliflozin ( 1 x 300mg tablet ) metformin XR ( 2 x 500mg tablet ) . Thus , 3 treatment period study : Treatment A : `` Reference '' treatment individual component . Treatment B : CANA/MET XR FDC , formulation 1 ; Treatment C : CANA/MET XR FDC , formulation 2 . Approximately 42 healthy adult participant randomly assign 1 3 treatment group , group receive three treatment different sequence ( 3-way crossover ) . The study consist 3 phase : Screening Phase approximately 3 week ( Days -22 -2 ) , Open-Label Treatment Phase consist 3 single-dose Treatment Periods 5 day ( Days -1 4 ) separate washout 10 14 day Day 1 Treatment Period , Follow-up Phase occur 7 10 day last study-related procedure Day 4 Treatment Period 3 . The total duration study 70 day participant .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Must sign inform consent document indicate understand purpose study procedure Must body mass index ( BMI ) 18 30 kg/m² , inclusive Must body weight less 50 kg Must blood pressure 90 140 mmHg inclusive , systolic , high 90 mmHg diastolic screen Must normal renal function evidence kidney damage ( include abnormality blood urine test ) History current clinically significant medical illness Use prescription nonprescription medication ( include vitamin herbal supplement ) History clinically significant allergy , especially know hypersensitivity intolerance drug lactose Known allergy heparin history heparin induce thrombocytopenia Donated blood blood product substantial loss blood within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Metformin</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>GLUMETZA®</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Fixed Dose Combination</keyword>
</DOC>